Indication
Enteropathy-Associated T-Cell Lymphoma
7 clinical trials
12 products
4 drugs
Clinical trial
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasStatus: Recruiting, Estimated PCD: 2024-12-01
Product
DR-01Clinical trial
Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Status: Withdrawn, Estimated PCD: 2026-03-15
Product
Brentuximab VedotinProduct
PembrolizumabClinical trial
Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2026-04-30
Product
WU-CART-007Clinical trial
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2019-11-01
Drug
cyclophosphamideProduct
DoxorubicinProduct
EtoposideProduct
LenalidomideProduct
PrednisoneProduct
VincristineClinical trial
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-05-03
Drug
mFOLFOX6Product
PralatrexateClinical trial
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-06-30
Drug
R-CHOPDrug
DocetaxelProduct
DuvelisibProduct
Oral azacitidineClinical trial
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2021-07-16